Alexion has cultivated several technology platforms to enable the development of new antibodies and proteins in the treatment of autoimmune disorders, inflammatory disorders and cancer. These assets include:
- Combinatorial Human Antibody Library Technology (CoALT), Alexion's proprietary antibody phage display platform. CoALT enables the creation of antibody libraries containing billions of different human or other mammalian antibody genes and the selection of new therapeutic targets.
- A proprietary antibody humanization technology that enables antibodies generated from non-human sources to be converted into antibodies largely comprising human-derived sequences.
- Unique skill in rapidly generating, selecting and implementing high-expressing mammalian cell lines to support all phases of research with new antibodies.